Precision oncology in metastatic colorectal cancer—from biology to medicine

F Di Nicolantonio, PP Vitiello, S Marsoni… - Nature reviews Clinical …, 2021 - nature.com
Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Liver cancer cell of origin, molecular class, and effects on patient prognosis

D Sia, A Villanueva, SL Friedman, JM Llovet - Gastroenterology, 2017 - Elsevier
Primary liver cancer is the second leading cause of cancer-related death worldwide and
therefore a major public health challenge. We review hypotheses of the cell of origin of liver …

Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology

AB Benson, AP Venook, MM Al-Hawary… - Journal of the National …, 2021 - jnccn.org
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

[HTML][HTML] Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by …

T Yoshino, D Arnold, H Taniguchi, G Pentheroudakis… - Annals of …, 2018 - Elsevier
The most recent version of the European Society for Medical Oncology (ESMO) consensus
guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was …

Pathological features and prognostication in colorectal cancer

K Chen, G Collins, H Wang, JWT Toh - Current Oncology, 2021 - mdpi.com
The prognostication of colorectal cancer (CRC) has traditionally relied on staging as defined
by the Union for International Cancer Control (UICC) and American Joint Committee on …

Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology

AB Benson, AP Venook, L Cederquist, E Chan… - Journal of the National …, 2017 - jnccn.org
This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic
therapy in metastatic disease. Considerations for treatment selection among 32 different …

Biomarker-guided therapy for colorectal cancer: strength in complexity

A Sveen, S Kopetz, RA Lothe - Nature Reviews Clinical Oncology, 2020 - nature.com
The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

From tumour heterogeneity to advances in precision treatment of colorectal cancer

CJA Punt, M Koopman, L Vermeulen - Nature reviews Clinical oncology, 2017 - nature.com
In recent years, the high heterogeneity of colorectal cancer (CRC) has become evident.
Hence, biomarkers need to be developed that enable the stratification of patients with CRC …

Epigenetic alterations in colorectal cancer: emerging biomarkers

Y Okugawa, WM Grady, A Goel - Gastroenterology, 2015 - Elsevier
Colorectal cancer (CRC) is a leading cause of cancer deaths worldwide. One of the
fundamental processes driving the initiation and progression of CRC is the accumulation of …

The molecular hallmarks of the serrated pathway in colorectal cancer

FDE De Palma, V D'argenio, J Pol, G Kroemer… - Cancers, 2019 - mdpi.com
Colorectal cancer (CRC) is a leading cause of cancer death worldwide. It includes different
subtypes that differ in their clinical and prognostic features. In the past decade, in addition to …